Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis.

ABSTRACT:

Purpose

Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate the effect of sequential therapeutic administration on the incidence of pneumonitis.

Materials and methods

In this retrospective study, 242 patients were included. Serial radiologic findings taken during and immediately after ICI treatment were reviewed. Factors that increased pneumonitis and the relationship between peri-ICI chemotherapy and the development of pneumonitis were evaluated.

Results

Pneumonitis developed in 23 patients (9.5%); severe pneumonitis (grade ≥ 3) oc

SUBMITTER: Jung J 

PROVIDER: S-EPMC7812016 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature